Drug Interaction Report

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of atrasentan, which is primarily metabolized by CYP450 3A4. When a single dose of atrasentan 10 mg was administered with ketoconazole, a potent CYP450 3A4 inhibitor, atrasentan systemic exposure (AUC) increased by 90%. The risk of adverse effects such as edema, hepatotoxicity and anemia may be increased with this combination. The interaction has not been studied with other, less potent CYP450 3A4 inhibitors.

MANAGEMENT: Caution is advised when atrasentan is used with potent CYP450 3A4 inhibitors. Patients should be monitored for edema, anemia and signs of hepatotoxicity such as nausea, vomiting, abdominal pain, dark urine, loss of appetite, itching and/or yellowing of the skin or eyes.

Alcohol can increase the nervous system side effects of nefazodone such as dizziness, drowsiness, and difficulty concentrating. Some people may also experience impairment in thinking and judgment. You should avoid or limit the use of alcohol while being treated with nefazodone. Do not use more than the recommended dose of nefazodone, and avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. Talk to your doctor or pharmacist if you have any questions or concerns.